BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear. Here, we report the case of a patient with metastatic lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. We calculated a structure model of this very rare type of mutated BRAF kinase to explain the molecular mechanism of drug resistance. This information may help to develop effective targeted therapies for cancers with non-V600 BRAF mutations.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.08.012DOI Listing

Publication Analysis

Top Keywords

lung adenocarcinoma
8
adenocarcinoma braf
8
braf g469l
8
g469l mutation
8
mutation refractory
8
refractory vemurafenib
8
lung cancer
8
non-v600 braf
8
braf mutations
8
braf
6

Similar Publications

Pancreatic ductal adenocarcinoma (PDAC) is characterized by its aggressive nature and dismal prognosis, largely attributed to its unique tumor microenvironment. However, the molecular mechanisms by which tumor-associated macrophages (TAMs) promote PDAC progression, particularly the role of β-catenin signaling in regulating TAM phenotype and function, remain incompletely understood. Initially, we performed comprehensive analyses of RNA-seq and single-cell RNA-seq (scRNA-seq) datasets to investigate OSM and LOXL2 expression patterns in PDAC.

View Article and Find Full Text PDF

Chest x-ray (CXR) is widely used for lung cancer screening in Japan. We evaluated the sensitivity and specificity of CXR in detecting early lung cancer and its histological types. We cross-referenced lung cancer municipality screening data with the regional cancer registry database.

View Article and Find Full Text PDF

Patient-derived tumor organoids (PDTOs) models have been widely used to investigate the response of primary cancer tissues to anti-cancer agents. Nonetheless, only few case study tried to establish PDTOs and test treatment response based on bone metastasis (BoM) tissues. Fresh BoM tissues were obtained from lung cancer (LC) patients who underwent spinal metastatic tumor surgery for PDTOs culture.

View Article and Find Full Text PDF

Distinguishing between primary adenocarcinoma (AC) and squamous cell carcinoma (SCC) within non-small cell lung cancer (NSCLC) tumours holds significant management implications. We assessed the performance of radiomics-based models in distinguishing primary there is from SCC presenting as lung nodules on Computed Tomography (CT) scans. We studied individuals with histopathologically proven adenocarcinoma or SCC type NSCLC tumours, detected as lung nodules on Chest CT.

View Article and Find Full Text PDF

Micropapillary adenocarcinoma (MPC) is an aggressive histological subtype of lung adenocarcinoma (LUAD). MPC is composed of small clusters of cancer cells exhibiting inverted polarity. However, the mechanism underlying its formation is poorly understood.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!